Novel agents in myeloma: an exciting saga

Cancer. 2009 Jan 15;115(2):236-42. doi: 10.1002/cncr.24040.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Dexamethasone / administration & dosage
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lenalidomide
  • Multiple Myeloma / drug therapy*
  • Pyrazines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use*
  • Thrombosis / chemically induced
  • Thrombosis / prevention & control

Substances

  • Boronic Acids
  • Immunosuppressive Agents
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Lenalidomide